EP Patent

EP3863618A1 — Methods of treating cancer with pi3k alpha inhibitors and metformin

Assigned to F Hoffmann La Roche AG · Expires 2021-08-18 · 5y expired

What this patent protects

Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K alpha inhibitor.

USPTO Abstract

Described herein are methods of treating PIK3CA-mutant cancer patients by administering metformin and a PI3K alpha inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP3863618A1
Jurisdiction
EP
Classification
—
Expires
2021-08-18
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.